sre-45 Antibody

What is CD45 and what makes it a significant target for immunological research?

CD45, also known as leukocyte common antigen (LCA), is a type I transmembrane protein tyrosine phosphatase receptor expressed on all differentiated hematopoietic cells except erythrocytes and plasma cells . This protein is encoded by the PTPRC gene located at chromosome 1q31.3-q32.1, consisting of 34 exons that produce a large protein with both extracellular and cytoplasmic domains .

The significance of CD45 as a research target stems from its essential role as a regulator of T- and B-cell antigen receptor signaling pathways . CD45 functions through:

• Direct interaction with components of antigen receptor complexes via its extracellular domain

• Activation of various Src family kinases required for antigen receptor signaling via its cytoplasmic phosphatase domain

• Participation in critical immune cell functions including B cell differentiation and receptor-mediated signaling cascades

With a canonical amino acid length of 1306 residues and a molecular mass of approximately 147.5 kilodaltons, CD45 serves as an invaluable marker for identifying and studying various immune cell populations .

What are the major isoforms of CD45 and their functional significance?

CD45 exists in multiple isoforms generated through alternative splicing of exons 4-6 (corresponding to protein regions A, B, and C) . This alternative splicing can generate up to eight different protein products with varying extracellular domains while maintaining identical cytoplasmic phosphatase domains.

The major isoforms include:

The differential expression of these isoforms has significant functional implications. For example, murine CD4+CD45RB^high cells contain effector T cells that can induce autoimmunity or inflammatory bowel disease, while CD4+CD45RB^low cells contain regulatory T cells that can prevent T cell-mediated diseases and allograft rejection .

How can I validate the specificity of CD45 antibodies in my experimental system?

Validating CD45 antibody specificity requires a multi-faceted approach:

• Positive and negative control tissues: Use tonsil tissue as a positive control where all lymphocytes and histiocytes should show strong membranous CD45 staining. Squamous epithelial cells within the same tissue should be completely CD45 negative, serving as an internal negative control .

• Orthogonal validation: While RNA expression comparison has limitations for validating immunohistochemical staining of ubiquitous hematolymphoid cells, correlation with RNA-seq data from repositories such as the Human Protein Atlas, FANTOM5, and GTEx projects can provide supporting evidence .

• Isoform-specific validation: When using antibodies targeting specific isoforms, confirm the expected staining pattern based on known expression profiles (e.g., CD45RO/RB expression on memory versus naïve T cell populations) .

• Functional verification: Assess whether the antibody produces the expected biological effects, such as the chA6 mAb's ability to induce apoptosis in CD4+CD45RO/RB^bright T cells, which should affect primarily effector/memory T cell populations .

• Cross-reactivity testing: Test the antibody against similar proteins or in systems where CD45 is not expressed to confirm absence of non-specific binding.

How can retro-orbital (r.o.) CD45 antibody labeling be used to distinguish tissue-resident from recently migrated immune cells?

Retro-orbital CD45 antibody labeling provides a powerful method to differentiate between tissue-resident and newly migrated immune cells, particularly antibody-secreting cells (ASCs) . The methodology involves:

• Principle: Intravenous injection of fluorochrome-conjugated anti-CD45 antibodies (typically CD45-PE) results in immediate labeling of all CD45+ cells in circulation and those accessible to blood, but not cells sequestered in tissues that are protected from blood flow.

• Protocol steps:

  • Administer CD45-PE antibody via retro-orbital injection (using appropriate anesthesia)

  • Allow a brief circulation period (5 minutes is standard, though this can be modified based on experimental needs)

  • Euthanize animals and harvest tissues of interest

  • Process tissues for single-cell suspensions

  • Perform additional surface staining for flow cytometry analysis

• Data interpretation:

  • CD45-PE^positive^ cells = cells in circulation or with direct access to circulation at the time of injection

  • CD45-PE^negative^ cells = tissue-resident cells protected from blood-borne antibody labeling

This technique is particularly valuable for tracking the migration and residency status of antibody-secreting cells but can be adapted for other CD45+ immune cell populations by incorporating additional lineage-specific markers .

What are the mechanisms by which anti-CD45 antibodies can modulate immune cell function?

Anti-CD45 antibodies can modulate immune cell function through several distinct mechanisms:

• Induction of activation-independent apoptosis: The chimeric A6 (chA6) monoclonal antibody that recognizes both RO and RB isoforms of CD45 has been shown to induce apoptosis in CD4+ T cells in a dose-dependent manner, independent of T cell activation. This effect is most pronounced in CD4+CD45RO/RB^bright cells, which represent effector/memory T cell populations .

• Selective depletion of specific subpopulations: Anti-CD45RB antibodies can selectively deplete CD45RB^high effector cells while preserving CD45RB^low regulatory T cells, leading to an inversion of the CD45RB^high/CD45RB^low T cell subset ratio. This selective depletion contributes to immunomodulatory effects observed in transplantation models .

• Interference with T cell receptor signaling: By targeting the extracellular domain of CD45, antibodies can interfere with its interaction with components of the antigen receptor complexes, thereby altering downstream signaling events essential for T cell activation .

• Induction of regulatory T cells: Some anti-CD45 antibodies, like chA6 mAb, can induce anergic CD4+ and CD8+ regulatory T cells that contribute to immunosuppression .

• Altered phosphatase activity: Binding of antibodies to the extracellular domain may induce conformational changes that affect the phosphatase activity of the cytoplasmic domain, impacting cellular signaling pathways .

Understanding these mechanisms is crucial for the rational design of CD45-targeting therapeutic approaches for autoimmunity, transplantation, and inflammatory diseases.

How can computational models be used to design antibodies with custom CD45 isoform specificity?

Computational modeling represents a cutting-edge approach for designing antibodies with tailored specificity profiles for CD45 isoforms. This methodology combines biophysics-informed modeling with experimental data to generate antibodies with either high specificity for a single isoform or cross-reactivity across multiple isoforms .

The process involves:

• Training data acquisition: Performing phage display experiments selecting antibodies against various combinations of CD45 isoforms to generate robust training datasets .

• Model development: Creating computational models that incorporate the biophysical principles of antibody-antigen interactions, trained on experimental selection data.

• Energy function optimization: Developing mathematical energy functions (E) associated with each binding mode (w) to predict interaction strength between antibody variants and target isoforms .

• Custom specificity design strategies:

  • For cross-specific antibodies: Jointly minimize the energy functions associated with all desired target isoforms

  • For highly specific antibodies: Minimize the energy function for the desired isoform while maximizing energy functions for undesired isoforms

• Experimental validation: Testing predicted antibody variants not present in the training set to assess the model's capacity to generate novel sequences with custom specificity profiles .

This computational approach offers significant advantages over traditional selection methods by:

• Reducing experimental bias

• Enabling rational design of complex binding profiles

• Predicting outcomes for new combinations of ligands

• Providing insights into the molecular determinants of binding specificity

What factors affect CD45 antibody performance in multi-parameter flow cytometry experiments?

Successful application of CD45 antibodies in multi-parameter flow cytometry requires consideration of several critical factors:

• Selection of appropriate clones and fluorophores:

  • Different CD45 antibody clones may have varying affinities for specific isoforms

  • Fluorophore brightness must be matched to the expected expression level of CD45 on target populations

  • Spectral overlap considerations are crucial when designing multi-color panels

• Antibody titration and concentration optimization:

  • Suboptimal antibody concentrations can lead to insufficient staining or excessive background

  • Each clone and fluorophore combination should be individually titrated

  • Standard titration involves testing serial dilutions to identify the concentration yielding optimal signal-to-noise ratio

• Compensation and fluorescence spreading:

  • CD45 is often brightly expressed, requiring careful compensation to prevent spreading into other channels

  • Single-stained controls with CD45 antibodies should be included for accurate compensation matrix calculation

• Fixation and permeabilization effects:

  • Some fixation methods can alter CD45 epitope accessibility

  • When combining CD45 surface staining with intracellular markers, verify that the fixation/permeabilization protocol preserves CD45 detection

• Buffer composition and staining conditions:

  • Presence of Fc receptor blocking reagents can improve specificity

  • Temperature and incubation time affect binding kinetics and should be standardized

  • Sodium azide in staining buffers helps prevent antibody internalization

• Sample-specific considerations:

  • Tissue-derived samples may require additional optimization compared to peripheral blood

  • Enzymatic tissue digestion can cleave CD45 epitopes, affecting antibody binding

  • Autofluorescence from certain tissues may interfere with CD45 detection

Careful optimization of these parameters is essential for generating reliable and reproducible flow cytometry data using CD45 antibodies.

How can I address weak or inconsistent CD45 antibody staining in immunohistochemistry?

When encountering weak or inconsistent CD45 antibody staining in immunohistochemistry, consider implementing these methodological solutions:

• Antigen retrieval optimization:

  • Test different antigen retrieval methods (heat-induced epitope retrieval with citrate buffer pH 6.0 vs. EDTA buffer pH 9.0)

  • Optimize retrieval duration and temperature

  • For formalin-fixed tissues, longer retrieval times may be necessary to unmask CD45 epitopes

• Antibody concentration and incubation parameters:

  • Titrate antibody concentration using positive control tissues

  • Extend primary antibody incubation time (overnight at 4°C vs. 1 hour at room temperature)

  • Consider using signal amplification systems for weak signals

• Detection system enhancements:

  • Switch to more sensitive detection methods (e.g., polymer-based systems or tyramide signal amplification)

  • Ensure detection reagents are fresh and properly stored

  • Optimize chromogen development time

• Tissue processing factors:

  • Excessive fixation can mask CD45 epitopes; standardize fixation protocols

  • Longer deparaffinization may improve staining in older specimens

  • Consider using freshly cut sections as prolonged storage can reduce antigenicity

• Clone selection considerations:

  • Different antibody clones recognize distinct epitopes; test alternative clones if one performs poorly

  • Recombinant monoclonal antibodies like MSVA-045R may offer more consistent results compared to some hybridoma-derived antibodies

• Technical validation approaches:

  • Always include positive controls (tonsil tissue) where lymphocytes and histiocytes should show strong membranous CD45 staining

  • Include negative controls (squamous epithelial cells in tonsil should be CD45 negative)

  • When troubleshooting, process control tissues alongside test tissues

What strategies can minimize non-specific binding when using CD45 antibodies in challenging tissue samples?

Non-specific binding can significantly impact CD45 antibody performance, particularly in tissues with high endogenous peroxidase activity or Fc receptor expression. Implement these methodological strategies:

• Enhanced blocking protocols:

  • Extended blocking with serum matching the host species of secondary antibody (20-60 minutes)

  • Dual blocking approach using both serum and commercial protein blockers

  • For tissues with high Fc receptor expression, include specific Fc receptor blocking reagents

• Buffer and reagent optimization:

  • Add 0.1-0.3% Triton X-100 to reduce hydrophobic interactions

  • Include 0.1-0.5% BSA in antibody diluent to reduce non-specific binding

  • Consider commercial antibody diluents specifically designed to reduce background

• Endogenous enzyme inactivation:

  • For tissues with high endogenous peroxidase (liver, kidney, bone marrow):

    • Use 3% hydrogen peroxide for 10-15 minutes prior to antibody application

    • For resistant samples, consider dual blocking with hydrogen peroxide and sodium azide

  • For alkaline phosphatase-based detection:

    • Include levamisole to block endogenous alkaline phosphatase

• Washing protocol enhancement:

  • Increase washing steps between reagent applications

  • Use PBS with 0.05-0.1% Tween-20 for more effective removal of unbound antibody

  • Consider implementing high-salt washes (PBS with 0.5M NaCl) for tissues with high background

• Antibody format selection:

  • Direct conjugates may reduce background by eliminating secondary antibody

  • F(ab')2 fragments can be used to eliminate Fc-mediated binding

  • Recombinant antibody formats may offer improved specificity profiles

• Tissue-specific pretreatments:

  • For melanin-containing tissues: Pretreatment with 10% hydrogen peroxide in PBS overnight

  • For lipid-rich tissues: Extended deparaffinization and use of detergent in buffers

  • For highly autofluorescent tissues: Sudan Black B treatment or specialized quenching reagents

Implementation of these approaches should be systematic, changing one variable at a time while maintaining appropriate controls to identify the most effective strategy for each specific tissue type.

How are CD45 antibodies being utilized in multiplex imaging systems for spatial immune profiling?

CD45 antibodies play a crucial role in multiplex imaging technologies for spatial immune profiling, offering insights into the distribution and interactions of immune cells within the tissue microenvironment:

• Multiplex immunohistochemistry (mIHC) applications:

  • CD45 serves as a foundational marker in immune cell panels, identifying all leukocytes

  • Sequential staining protocols incorporate CD45 with other lineage markers to define specific immune subsets in spatial context

  • Tyramide signal amplification allows multiplexing of up to 8-10 markers on a single slide, with CD45 typically included in early staining rounds

• Imaging mass cytometry (IMC) implementations:

  • Metal-conjugated CD45 antibodies enable high-dimensional analysis (40+ markers)

  • CD45 is often used for initial segmentation of immune vs. non-immune cells

  • Resolution at subcellular level allows precise localization of CD45 expression

• Spatial transcriptomics integration:

  • CD45 antibody staining guides region selection for spatial transcriptomics

  • Combined protein (CD45) and RNA analysis reveals relationships between CD45 isoform expression and transcriptional programs

  • Computational integration of CD45 protein expression with RNA signatures enhances immune cell classification

• Artificial intelligence augmentation:

  • Machine learning algorithms use CD45 staining patterns to identify immune cell clusters

  • Deep learning approaches can segment CD45+ cells and classify subtypes based on morphology and additional markers

  • Quantitative spatial metrics analyze CD45+ cell proximity to other cell types (e.g., tumor cells)

• Clinical research applications:

  • CD45 spatial distribution patterns correlate with immunotherapy response

  • Quantification of CD45+ cell infiltration at tumor margins provides prognostic information

  • Spatial relationships between CD45 subsets reveal immune regulatory mechanisms in disease contexts

Future developments include higher-plex systems incorporating multiple CD45 isoform-specific antibodies simultaneously, integration with single-cell genomics, and development of standardized analysis pipelines for cross-study comparisons.

What role might CD45-targeted antibodies play in next-generation immunotherapeutic approaches?

CD45-targeted antibodies show significant promise for diverse immunotherapeutic applications, with several mechanisms and approaches under investigation:

• Immunomodulation for transplantation:

  • Anti-CD45RB antibodies have demonstrated potent immunomodulatory effects that prolong allograft survival in multiple transplantation models

  • Chimeric A6 (chA6) monoclonal antibody recognizing both RO and RB isoforms can induce long-term engraftment and donor-specific tolerance

  • These antibodies work through selective depletion of CD45RB^high effector cells while preserving or inducing regulatory T cell populations

• Targeted immune cell depletion:

  • CD45 antibodies conjugated to toxins or radionuclides can selectively deplete leukemic cells while sparing hematopoietic stem cells

  • This approach shows promise for conditioning regimens prior to bone marrow transplantation

  • Selective targeting of specific CD45 isoforms could enable precision depletion of pathogenic immune cell subsets

• CAR-T cell engineering:

  • CD45 isoform-specific targeting domains can be incorporated into chimeric antigen receptors

  • This approach enables selective targeting of malignant populations expressing specific CD45 isoform patterns

  • Computational design techniques can create custom specificity profiles for optimal therapeutic index

• Bispecific antibody approaches:

  • CD45-targeted bispecific antibodies can redirect cytotoxic T cells to CD45+ malignant cells

  • Isoform-specific targeting can enhance selectivity for malignant versus normal cells

  • Combinatorial targeting (CD45 plus lineage-specific antigens) improves specificity

• Antibody-drug conjugates (ADCs):

  • CD45-targeted ADCs deliver cytotoxic payloads specifically to CD45+ cells

  • Differential expression levels of CD45 between normal and malignant cells creates a therapeutic window

  • Next-generation ADCs with cleavable linkers optimize intracellular drug delivery

• Immune checkpoint modulation:

  • CD45 phosphatase activity modulates T cell receptor signaling thresholds

  • Antibodies targeting specific CD45 domains can fine-tune T cell activation

  • This approach could complement existing checkpoint inhibitors by operating through distinct mechanisms

The design of these therapeutic antibodies increasingly leverages computational modeling to optimize specificity profiles, potentially creating antibodies with custom reactivity to specific CD45 isoforms while sparing others .

How can researchers optimize CD45 antibody selection for identifying microglia in neuroinflammation studies?

Optimizing CD45 antibody selection for microglial identification in neuroinflammation research requires careful consideration of several methodological factors:

• Expression level discrimination strategy:

  • Microglia typically express intermediate levels of CD45 (CD45^int^) compared to infiltrating peripheral leukocytes (CD45^high^)

  • Select antibody clones and fluorophores that provide sufficient dynamic range to clearly distinguish these expression levels

  • Validate the resolution capability using positive controls (e.g., LPS-stimulated brain tissue containing both resident microglia and infiltrating cells)

• Combinatorial marker approach:

  • Pair CD45 with microglial-specific markers such as P2RY12, TMEM119, or Sall1

  • Include markers that distinguish infiltrating myeloid cells (e.g., CCR2, Ly6C)

  • This multi-parameter strategy improves discrimination between resident microglia and infiltrating macrophages

• Clone selection considerations:

  • Test multiple CD45 antibody clones as epitope accessibility may differ in CNS tissue

  • Some clones may preferentially recognize specific CD45 isoforms expressed by microglia

  • Compare staining patterns of different clones in both control and neuroinflammatory conditions

• Tissue processing optimization:

  • CD45 epitopes may be sensitive to fixation; optimize fixation duration

  • For flow cytometry applications, gentle tissue dissociation is critical to preserve CD45 expression

  • For imaging applications, test multiple antigen retrieval methods to optimize signal-to-noise ratio

• Application-specific recommendations:

  • Flow cytometry: Bright fluorophores (PE, APC) coupled with dump channels to exclude debris and dead cells

  • Immunohistochemistry: Signal amplification methods may be required for optimal visualization

  • Live imaging: Minimally disruptive antibody fragments to avoid activation of microglia

• Validation in disease models:

  • Confirm microglial identification strategy across different neuroinflammatory conditions

  • Expression of CD45 on microglia may increase during activation; adjust gating strategies accordingly

  • Include age-matched controls as microglial CD45 expression can change with aging

By implementing these methodological considerations, researchers can more accurately identify and characterize microglia in neuroinflammation studies, enhancing the reliability and reproducibility of their findings.